Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

Author's Avatar
Jun 03, 2023

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival